• Fulfilling

    Potential

    With the Science of Enzymes

  • Fulfilling

    Potential

    In the Treatment of 

    Gastrointestinal and Rare Diseases

  • Helping

    Patients

    Fulfill Their Potential

News & Media

Data from the ASSURE Study of Long-Term Use of RELiZORB® (iMMOBILIZED LIPASE) CARTRIDGE Published in Journal of Pediatric Gastroenterology and Nutrition

Aug 02, 2018

Largest Prospective Trial of Enteral Feeding in Cystic Fibrosis Shows Sustained Use of RELiZORB Can Help Hydrolyze Fatty Acids and Normalize Absorption

Alcresta Therapeutics Announces RELiZORB® (iMMOBILIZED LIPASE) CARTRIDGE has been Issued a Unique Q-Code (Q9994) by CMS

Jun 18, 2018

WARREN, N.J. – June 18, 2018 – Alcresta Therapeutics, Inc. today announced the issuance of a unique Q-code by CMS for its digestive enzyme cartridge RELiZORB. RELiZORB (iMMOBILIZED LIPASE) CARTRIDGE is an in-line digestive enzyme cartridge and is indicated for use in pediatric patients (ages 5 years and above) and adult patients to hydrolyze fats in enteral formula.  The code, Q9994, is effective July 1, 2018.  CMS has instructed Medicare Administrative Contractors to add Q9994 to the relevant code set as of that date.

Alcresta Therapeutics, Inc. Presented Results at the North American Cystic Fibrosis Conference from the ASSURE Study: An Evaluation of the Long-Term Use of RELiZORB®

Nov 06, 2017

Four additional studies with RELiZORB were presented by investigators at leading cystic fibrosis centers